

2025 5th Annual Update in Neuro-Oncology Publications

1. Aizer AA, Lamba N, Ahluwalia MS, Aldape K, Boire A, Brastianos PK, Brown PD, Camidge DR, Chiang VL, Davies MA, Hu LS, Huang RY, Kaufmann T, Kumthekar P, Lam K, Lee EQ, Lin NU, Mehta M, Parsons M, Reardon DA, Sheehan J, Soffietti R, Tawbi H, Weller M, Wen PY. Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. *Neuro Oncol.* 2022; 24:1613-1646. PMID: 35762249; PMCID: [PMC9527527](#).
2. Aquilanti E, Wen PY. Advanced molecular diagnostic tools: A step closer to precision medicine in neuro-oncology. *Neuro Oncol.* 2023 Oct 3;25(10):1750-1751. doi: 10.1093/neuonc/noad132. PMID: 37503808; PMCID: [PMC10547505](#).
3. Arrillaga-Romany I, Lassman A, McGovern SL, Mueller S, Nabors B, van den Bent M, Vogelbaum MA, Allen JE, Melemed AS, Tarapore RS, Wen PY, Cloughesy T. ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma. *Neuro Oncol.* 2024 May 3;26(Supplement_2):S173-S181. doi: 10.1093/neuonc/noae031. PMID: 38445964; PMCID: [PMC11066938](#).
4. Avila EK, Tobochnik S, Inati SK, Koekkoek JAF, McKhann GM, Riviello JJ, Rudà R, Schiff D, Tatum WO, Templer JW, Weller M, Wen PY. Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current management. *Neuro Oncol.* 2024 Jan 5;26(1):7-24. doi: 10.1093/neuonc/noad154. PMID: 37699031; PMCID: [PMC10768995](#).
5. Batchelor TT, Giri S, Ruppert AS, Geyer SM, Smith SE, Mohile N, Swinnen LJ, Friedberg JW, Kahl BS, Bartlett NL, Hsi ED, Cheson BD, Wagner-Johnston N, Nayak L, Leonard JP, Rubenstein JL. Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101. *Blood Adv.* 2024 Jun 25;8(12):3189-3199. doi: 10.1182/bloodadvances.2023011657. PMID: 38598710; PMCID: [PMC11225669](#).
6. Budhu JA, Chukwueke UN, Jackson S, Lee EQ, McFaline-Figueroa JR, Willmarth N, Dalmage M, Kawachi I, Arons D, Chang SM, Galanis E, Hervey-Jumper SL, Wen PY, Porter AB. Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort. *Neuro Oncol.* 2024 Apr 5;26(4):596-608. doi: 10.1093/neuonc/noad242. PMID: 38071654; PMCID: [PMC10995510](#).
7. Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, Nikiforow S, Carter BS, Curry WT, Gallagher K, Maus MV. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. *N Engl J Med.* 2024 Apr 11;390(14):1290-1298. doi: 10.1056/NEJMoa2314390. Epub 2024 Mar 13. PMID: 38477966; PMCID: [PMC11162836](#).
8. Ellingson BM, Sanvito F, Cloughesy TF, Huang RY, Villanueva-Meyer JE, Pope WB, Barboriak DP, Shankar LK, Smits M, Kaufmann TJ, Boxerman JL, Weller M, Galanis E, Groot J, Gilbert MR, Lassman AB, Shiroishi MS, Nabavizadeh A, Mehta M, Stupp R, Wick W, Reardon DA, Vogelbaum MA, van den Bent M, Chang SM, Wen PY. A Neuroradiologist's Guide to Operationalizing the Response Assessment in Neuro-

Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults. *AJNR Am J Neuroradiol*. 2024 Jun 28;ajnr.A8396. doi: 10.3174/ajnr.A8396. PMID: 38926092; PMCID: [PMC11630866](#).

9. Fallah J, Brave MH, Weinstock C, Mehta GU, Bradford D, Gittleman H, Bloomquist EW, Charlab R, Hamed SS, Miller CP, Dorff SE, Chambers WA, Mixter BD, Dinin J, Pierce WF, Ricks TK, Tang S, Donoghue M, Pazdur R, Amiri-Kordestani L, Ibrahim A, Beaver JA. FDA approval summary: belzutifan for von Hippel-Lindau disease associated tumors. *Clin Cancer Res*. 2022 Jun 21;clincanres.1054.2022-4-4 11:16:38.037. PMID: 35727604; PMCID: [PMC9669093](#).
10. Ferreri AJM, Calimeri T, Cwynarski K, Dietrich J, Grommes C, Hoang-Xuan K, Hu LS, Illerhaus G, Nayak L, Ponzoni M, Batchelor TT. Primary central nervous system lymphoma. *Nat Rev Dis Primers*. 2023 Jun 15;9(1):29. doi: 10.1038/s41572-023-00439-0. PMID: 37322012; PMCID: [PMC10637780](#).
11. Galldiks N, Kaufmann TJ, Vollmuth P, Lohmann P, Smits M, Veronesi MC, Langen KJ, Rudà R, Albert NL, Hattingen E, Law I, Hutterer M, Soffietti R, Vogelbaum MA, Wen PY, Weller M, Tonn JC. Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO group. *Neuro Oncol*. 2024 Jul 5;26(7):1181-1194. doi: 10.1093/neuonc/noae049. PMID: 38466087; PMCID: [PMC11226881](#).
12. Gonzalez Castro LN, Arrillaga-Romany IC, Batchelor TT. Challenges and Opportunities for Clinical Trials in Patients with Glioma. *JAMA Neurol*. 2023 Mar 1;80(3):227-228. doi: 10.1001/jamaneurol.2022.4924. [PMID: 36648934](#).
13. Mehari M, Sibih Y, Dada A, Chang SM, Wen PY, Molinaro AM, Chukwueke UN, Budhu JA, Jackson S, McFaline-Figueroa JR, Porter A, Hervey-Jumper SL. Enhancing neuro-oncology care through equity-driven applications of artificial intelligence. *Neuro Oncol*. 2024 Aug 19;noae127. doi: 10.1093/neuonc/noae127. PMID: 39159285; PMCID: [PMC11534320](#).
14. Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF; INDIGO Trial Investigators. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. *N Engl J Med*. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. PMID: 37272516; PMCID: [PMC11445763](#).
15. Miller JJ, Gonzalez Castro LN, McBrayer S, Weller M, Cloughesy T, Portnow J, Andronesi O, Barnholtz-Sloan JS, Baumert BG, Berger MS, Bi WL, Bindra R, Cahill DP, Chang SM, Costello JF, Horbinski C, Huang RY, Jenkins RB, Ligon KL, Mellinghoff IK, Nabors LB, Platten M, Reardon DA, Shi DD, Schiff D, Wick W, Yan H, von Deimling A, van den Bent M, Kaelin WG, Wen PY. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. *Neuro Oncol*. 2023 Jan 5;25(1):4-25. doi: 10.1093/neuonc/noac207.

PMID: 36239925; PMCID: [PMC9825337](#).

16. Ospina JP, Wen PY. Medical and neurologic management of brain tumor patients. *Curr Opin Neurol*. 2024 Sep 3. doi: 10.1097/WCO.0000000000001315. Epub 2024 Sep 2. [PMID: 39221926](#).
17. Wang JZ, Landry AP, Raleigh DR, Sahm F, Walsh KM, Goldbrunner R, Yefet LS, Tonn JC, Gui C, Ostrom QT, Barnholtz-Sloan J, Perry A, Ellenbogen Y, Hanemann CO, Jungwirth G, Jenkinson MD, Tabatabai G, Mathiesen TI, McDermott MW, Tatagiba M, la Fougère C, Maas SLN, Galldiks N, Albert NL, Brastianos PK, Ehret F, Minniti G, Lamszus K, Ricklefs FL, Schittenhelm J, Drummond KJ, Dunn IF, Pathmanaban ON, Cohen-Gadol A, Sulman EP, Tabouret E, Le Rhun E, Mawrin C, Moliterno J, Weller M, Bi WL, Gao A, Yip S, Niyazi M; International Consortium on Meningiomas (ICOM); Aldape K, Wen PY, Short S, Preusser M, Nassiri F, Zadeh G. Meningioma: International Consortium on Meningiomas (ICOM) consensus review on scientific advances & treatment paradigms for clinicians, researchers, and patients. *Neuro Oncol*. 2024 Oct 3;26(10):1742-1780. doi: 10.1093/neuonc/noae082. PMID: 38695575; PMCID: [PMC11449035](#).
18. Wen PY, van den Bent M, Youssef G, Cloughesy TF, Ellingson BM, Weller M, Galanis E, Barboriak DP, de Groot J, Gilbert MR, Huang R, Lassman AB, Mehta M, Molinaro AM, Preusser M, Rahman R, Shankar LK, Stupp R, Villanueva-Meyer JE, Wick W, Macdonald DR, Reardon DA, Vogelbaum MA, Chang SM. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. *J Clin Oncol*. 2023 Nov 20;41(33):5187-5199. doi: 10.1200/JCO.23.01059. Epub 2023 Sep 29. PMID: 37774317; PMCID: [PMC10860967](#).
19. Wilcox JA, Chukwueke UN, Ahn MJ, Aizer AA, Bale TA, Brandsma D, Brastianos PK, Chang S, Daras M, Forsyth P, Garzia L, Glantz M, Oliva ICG, Kumthekar P, Le Rhun E, Nagpal S, O'Brien B, Pentsova E, Lee EQ, Remsik J, Rudà R, Smalley I, Taylor MD, Weller M, Wefel J, Yang JT, Young RJ, Wen PY, Boire AA; International Leptomeningeal Metastasis Collaborative. Leptomeningeal metastases from solid tumors: A SNO and ASCO consensus review on clinical management and future directions. *Neuro Oncol*. 2024 Jun 21;noae103. doi: 10.1093/neuonc/noae103. PMID: 38902944; PMCID: [PMC11449070](#).
20. Winkler F, Venkatesh HS, Amit M, Batchelor T, Demir IE, Deneen B, Gutmann DH, Hervey-Jumper S, Kurer T, Mabbott D, Platten M, Rolls A, Sloan EK, Wang TC, Wick W, Venkataramani V, Monje M. Cancer neuroscience: State of the field, emerging directions. *Cell*. 2023 Apr 13;186(8):1689-1707. doi: 10.1016/j.cell.2023.02.002. PMID: 37059069; PMCID: [PMC10107403](#).